ainitfunny
Saved, to glorify God.
"What could go wrong?" LOTS. WHY don't they put these dangerous prospective experiments to a vote of the people? Other scientists have revealed that the live vaccines STILL HAVE THE ABILITY TO MUTATE! Some scientists are WARNING against these proposed vaccines. WHO doctors are not happy with the idea.
https://www.federalregister.gov/art...ccines-for-rabies-virus-and-ebola-and-marburg
Home
Sections
Browse
Search
Policy
Learn
Blog
My FR
The Federal Register
The Daily Journal of the United States Government
Notice
Prospective Grant of Exclusive License: Multivalent Vaccines for Rabies Virus and Ebola and Marburg (Filoviruses)
A Notice by the National Institutes of Health on 03/31/2014
Email
Twitter
Facebook
Previous Document Next Document
Legal Disclaimer
Font Controls
Increase
Decrease
Sans
Serif
PDF DEV Print Public Inspection
Publication Date:
Monday, March 31, 2014
Agencies:
Department of Health and Human Services
National Institutes of Health
Dates:
Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before April 30, 2014 will be considered.
Comments Close:
04/30/2014
Entry Type:
Notice
Action:
Notice.
Document Citation:
79 FR 18039
Page:
18039 -18040 (2 pages)
Document Number:
2014-07023
Shorter URL:
https://federalregister.gov/a/2014-07023
Action
Notice.
Summary
This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 404, that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of a an exclusive license to practice the following invention as embodied in the following patent applications: E-032-2011/0, Blaney et al.,“Multivalent Vaccines for Rabies Virus and Filoviruses,” U.S. Patent Application Number 61/439,046, filed on February 3, 2011, PCT Application Number PCT/US2012/23575, filed on February 2, 2012, U.S. Patent Application Number 13/983,545, filed on August 2, 2013, European Patent Application Number 12702953.6, filed on February 2, 2012, and Canadian Patent Application Number 2826594, filed on February 2, 2012, to Exxell BIO, Inc., having a place of business in Shoreview, Minnesota, United States of America. The patent rights in these inventions have been assigned to the United States of America and Thomas Jefferson University.
Table of Contents Back to Top
DATES:
ADDRESSES:
SUPPLEMENTARY INFORMATION:
DATES: Back to Top
Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before April 30, 2014 will be considered.
ADDRESSES: Back to Top
Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Peter Soukas, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Email: ps193c@nih.gov; Telephone: (301) 435-4646; Facsimile: (301) 402-0220.
SUPPLEMENTARY INFORMATION: Back to Top
No vaccine candidates against Ebola virus (EBOV) or Marburg virus (MARV) are nearing licensure, and the need to develop a safe and efficacious vaccine against filoviruses continues. Whereas several preclinical and clinical vaccine candidates against EBOV or MARV exist (please see below for further elaboration), their further development is a major challenge based on safety concerns, pre-existing vector immunity, issues such as manufacturing, dosage, and marketability, and funding for development. The inventors have developed a new platform based on live or chemically inactivated (killed) rabies virus (RABV) virions containing EBOV glycoprotein (GP) in their envelope. In preclinical trials, immunization with such recombinant RABV virions provided excellent protection in mice against lethal challenge with the mouse adapted EBOV and RABV. More specifically, the inventors have developed a trivalent filovirus vaccine based on killed rabies virus virions for use in humans to confer protection from all medically relevant filoviruses and RABV. Two additional vectors containing EBOV Sudan GP or MARV GP are planned to be constructed in addition to the previously developed EBOV Zaire GP containing vaccine. Live attenuated vaccines have been developed for use in at risk nonhuman primate populations in Africa and inactivated vaccines have been developed for use in humans.
The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404. The prospective exclusive license may be granted unless, within thirty (30) days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.
The fields of use may be limited to (1) inactivated vaccines against rabies virus and filoviruses for use in humans and (2) live attenuated vaccines against rabies virus and filoviruses for use in non-human animals.
Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.
Dated: March 26, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.
[FR Doc. 2014-07023 Filed 3-28-14; 8:45 am]
BILLING CODE 4140-01-P
Home
Home
Sections
Money
Environment
World
Science & Technology
Business & Industry
Health & Public Welfare
Browse
Agencies
Topics
Dates
Public Inspection
Executive Orders
Search
Document Search
Advanced Document Search
Events Search
Unified Agenda Search
Public Inspection Search
Policy
About Us
Legal Status
Contact Us
Privacy
Accessibility
FOIA
No Fear Act
Continuity Information
Learn
User Information
About Public Inspection
Document Drafting & Research
Related Resources
Tutorials, History, and Statistics
Regulatory Journals
Regulatory Improvement
Developers
Site Feedback
https://www.federalregister.gov/art...ccines-for-rabies-virus-and-ebola-and-marburg
Home
Sections
Browse
Search
Policy
Learn
Blog
My FR
The Federal Register
The Daily Journal of the United States Government
Notice
Prospective Grant of Exclusive License: Multivalent Vaccines for Rabies Virus and Ebola and Marburg (Filoviruses)
A Notice by the National Institutes of Health on 03/31/2014
Previous Document Next Document
Legal Disclaimer
Font Controls
Increase
Decrease
Sans
Serif
PDF DEV Print Public Inspection
Publication Date:
Monday, March 31, 2014
Agencies:
Department of Health and Human Services
National Institutes of Health
Dates:
Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before April 30, 2014 will be considered.
Comments Close:
04/30/2014
Entry Type:
Notice
Action:
Notice.
Document Citation:
79 FR 18039
Page:
18039 -18040 (2 pages)
Document Number:
2014-07023
Shorter URL:
https://federalregister.gov/a/2014-07023
Action
Notice.
Summary
This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 404, that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of a an exclusive license to practice the following invention as embodied in the following patent applications: E-032-2011/0, Blaney et al.,“Multivalent Vaccines for Rabies Virus and Filoviruses,” U.S. Patent Application Number 61/439,046, filed on February 3, 2011, PCT Application Number PCT/US2012/23575, filed on February 2, 2012, U.S. Patent Application Number 13/983,545, filed on August 2, 2013, European Patent Application Number 12702953.6, filed on February 2, 2012, and Canadian Patent Application Number 2826594, filed on February 2, 2012, to Exxell BIO, Inc., having a place of business in Shoreview, Minnesota, United States of America. The patent rights in these inventions have been assigned to the United States of America and Thomas Jefferson University.
Table of Contents Back to Top
DATES:
ADDRESSES:
SUPPLEMENTARY INFORMATION:
DATES: Back to Top
Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before April 30, 2014 will be considered.
ADDRESSES: Back to Top
Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Peter Soukas, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Email: ps193c@nih.gov; Telephone: (301) 435-4646; Facsimile: (301) 402-0220.
SUPPLEMENTARY INFORMATION: Back to Top
No vaccine candidates against Ebola virus (EBOV) or Marburg virus (MARV) are nearing licensure, and the need to develop a safe and efficacious vaccine against filoviruses continues. Whereas several preclinical and clinical vaccine candidates against EBOV or MARV exist (please see below for further elaboration), their further development is a major challenge based on safety concerns, pre-existing vector immunity, issues such as manufacturing, dosage, and marketability, and funding for development. The inventors have developed a new platform based on live or chemically inactivated (killed) rabies virus (RABV) virions containing EBOV glycoprotein (GP) in their envelope. In preclinical trials, immunization with such recombinant RABV virions provided excellent protection in mice against lethal challenge with the mouse adapted EBOV and RABV. More specifically, the inventors have developed a trivalent filovirus vaccine based on killed rabies virus virions for use in humans to confer protection from all medically relevant filoviruses and RABV. Two additional vectors containing EBOV Sudan GP or MARV GP are planned to be constructed in addition to the previously developed EBOV Zaire GP containing vaccine. Live attenuated vaccines have been developed for use in at risk nonhuman primate populations in Africa and inactivated vaccines have been developed for use in humans.
The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404. The prospective exclusive license may be granted unless, within thirty (30) days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.
The fields of use may be limited to (1) inactivated vaccines against rabies virus and filoviruses for use in humans and (2) live attenuated vaccines against rabies virus and filoviruses for use in non-human animals.
Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.
Dated: March 26, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.
[FR Doc. 2014-07023 Filed 3-28-14; 8:45 am]
BILLING CODE 4140-01-P
Home
Home
Sections
Money
Environment
World
Science & Technology
Business & Industry
Health & Public Welfare
Browse
Agencies
Topics
Dates
Public Inspection
Executive Orders
Search
Document Search
Advanced Document Search
Events Search
Unified Agenda Search
Public Inspection Search
Policy
About Us
Legal Status
Contact Us
Privacy
Accessibility
FOIA
No Fear Act
Continuity Information
Learn
User Information
About Public Inspection
Document Drafting & Research
Related Resources
Tutorials, History, and Statistics
Regulatory Journals
Regulatory Improvement
Developers
Site Feedback